Amazon (AMZN) Q4 Estimates, PT Raised at BMO Capital on Prime Strength
- S&P little changed as energy weighs but financials edge up
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- Fed's Yellen says 'makes sense' to gradually raise interest rates
- UPDATE: Fed Beige Book: Wages gain modestly in most areas amid tight job market
- Mallinckrodt (MNK) Announces FTC Settlement
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BMO Capital analyst Daniel Salmon said while Q3 revenues estimates for Amazon.com (NASDAQ: AMZN) look appropriate they are raising their already above consensus estimates for 4Q due to increased confidence in Prime growth. The firm reiterated an Outperform rating and raised its price target to $900.00 (from $875.00).
"We believe there were 26 million more Prime members heading into 2H16 compared to 2H15, very significant due to the fact that Prime members tend to spend more than non-Prime members," Salmon said. They now estimate there were 76 million Prime members as of 2Q16 and expect this to grow to 93 million by year-end 2016. They believe the Prime member base can reach 163 million by FY18E.
The firm now estimates 4Q16 revenue of $46.0B, up from $45.6B, and ahead of the Street's $44.6B. The firm rasied FY 2016 EPS estimates from $5.61 to $5.86 and FY 2017 EPS from $9.97 to $10.29/
They estimate Amazon will record ~$6.9 billion of Prime subscription fees as revenue in 2016E, up from ~$4.5 billion last year. They believe this number could approach ~$14 billion by FY18E.
They believe the majority of Amazon's unearned revenue, additions to unearned revenue, and amortization of unearned revenue are due to Prime subscription fees.
Shares of Amazon.com closed at $789.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
- UBS Cuts Price Target on Morgan Stanley (MS) to $49; Reiterates Buy
- Deutsche Bank Cuts Price Target on Neurocrine Biosciences (NBIX) Following Study
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!